A Phase I Study of Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Trial Profile

A Phase I Study of Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Dec 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2016.
    • 05 Dec 2016 Status changed from recruiting to withdrawn prior to enrolment due to lack of accrual .
    • 11 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top